CEACAM5 and pancreatic adenocarcinoma: Another single-arm, open-label phase Ib trial (n=1) reported one case of pancreatic adenocarcinoma with liver metastases who achieved complete metabolic response as assessed by PET-CT after receiving CEA-targeted CAR-T therapy.